Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation (NCT03140631) | Clinical Trial Compass
CompletedPhase 4
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
United States153 participantsStarted 2017-03-23
Plain-language summary
The objective of this study is to evaluate the safety, efficacy and efficiency of rapid anticoagulation reversal with protamine sulfate versus routine activated clotting time (ACT) monitoring in patients undergoing catheter based ablation of atrial fibrillation.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient's referred for radiofrequency ablation (RFA) or cryoablation for atrial fibrillation or atrial flutter (left atrial).
* Age ≥ 18 year
* Patients who are mentally and linguistically able to understand the aim of the trial, comply with the trial protocol, verbally acknowledge the risks, benefits, and alternatives in this trial.
Exclusion Criteria:
* Previous intolerance or allergy to heparin products.
* Current or prior administration of protamine products
* History of femoral access site complications including hematoma, AV fistula, pseudoaneurysm, aneurysm.
* Known lower extremity venous thrombosis.
* Coagulopathy or blood dyscrasias.
* Active malignancy.
* Thrombocytosis (platelet count \>600k/ul) or thrombocytopenia (platelet count \<100k/ul)
* Planned use of vascular closure device